Why It Matters
The sizable Series A underscores strong investor confidence and provides Zag Bio with the resources to fast‑track its therapeutic programs, potentially reshaping the diabetes treatment landscape and attracting further market interest.
Deal Summary
Zag Bio, a Cambridge‑based biotech startup, secured $80 million in a Series A financing round led by T1D Fund and Polaris Partners. The new capital will support the company’s product development and growth initiatives.
Comments
Want to join the conversation?
Loading comments...